Aug 09, 2019 0 NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock
Apr 17, 2019 0 NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication
Apr 01, 2019 0 NovaBay Pharmaceuticals Announces Investments of $5 Million to Support U.S. Avenova Commercialization Strategy
Mar 12, 2019 0 NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy
Jan 07, 2019 0 NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales and Introduces 2019 Net Sales Guidance
Nov 07, 2018 0 NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018
Aug 30, 2018 0 NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6
Jan 08, 2018 0 NovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full Year
Dec 22, 2017 0 NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreement
Dec 21, 2017 0 NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
Sep 20, 2017 0 NovaBay Pharmaceuticals Receives Notification of Noncompliance with Additional NYSE American Continued Listing Standards
Sep 05, 2017 0 NovaBay Pharmaceuticals to Present at Rodman & Renshaw 19th Annual Global Investment Conference
Aug 03, 2017 0 NovaBay Pharmaceuticals to Hold 2017 Second Quarter Conference Call on August 10, 2017
Mar 23, 2017 0 NovaBay Pharmaceuticals Reports 2016 Full Year and Fourth Quarter Financial Results and Provides 2017 Financial Guidance
Mar 16, 2017 0 NovaBay Pharmaceuticals to Hold 2016 Fourth Quarter and Full Year Conference Call on March 23, 2017
Mar 09, 2017 0 NovaBay Pharmaceuticals to Present Features and Benefits of the intelli-Case at FDA Public Advisory Meeting
Oct 31, 2016 0 NovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements
Sep 19, 2016 0 NovaBay Pharmaceuticals’ Auriclosene® Demonstrates Statistically Significant and Clinically Meaningful Results in Phase 2b Study for the Prevention of Urinary Catheter Blockage and Encrustation
Sep 12, 2016 0 NovaBay Pharmaceuticals’ Neutrox® Product Line Receives CE Mark and ISO Certification for the European Union
Sep 06, 2016 0 NovaBay Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
Jun 13, 2016 0 NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer
May 03, 2016 0 Clinical Data Presented at ARVO Showing NovaBay’s Avenova Reduces Bacteria on Ocular Skin Surface by More than 90%
Apr 06, 2016 0 NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two-Tranche Private Placement
Feb 25, 2016 0 NovaBay Pharmaceuticals to Hold 2015 Fourth Quarter and Full Year Conference Call on March 3
Jan 11, 2016 0 NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million
Nov 19, 2015 0 NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova Commercialization and Reports Third Quarter Financial Results
Oct 08, 2015 0 NovaBay Pharmaceuticals Provides Update on Avenova Sales Growth, Reports Progress with intelli-Case Test Market Launch and Product Pipeline Advancement
Sep 24, 2015 0 NovaBay Pharmaceuticals Announces Partnership With ALPHAEON To Bring Avenova To Ophthalmologists And Their Patients Across the U.S.
Sep 16, 2015 0 NovaBay Pharmaceuticals Signs Agreement with Nation’s Second Largest Independent Optometry Group, ALLDocs
Sep 02, 2015 0 NovaBay Pharmaceuticals Signs Distribution Agreement to Make Avenova Available in New Zealand
Jun 09, 2015 0 NovaBay Pharmaceuticals Conference Call Today, June 9th, 2015, at 12:00 p.m. Eastern Time
Jun 04, 2015 0 FDA Clears NovaBay Pharmaceuticals’ New High-Tech Device, intelli-Case, for Safely Disinfecting Contact Lenses with Hydrogen Peroxide
May 14, 2015 0 NovaBay Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update
May 11, 2015 0 NovaBay Pharmaceuticals to Feature Key Opinion Leaders in Ophthalmology and Optometry at Analyst and Investor Day Event on May 19
May 06, 2015 0 New Laboratory Study Shows that NovaBay Pharmaceuticals’ Avenova Completely Inactivates the Bacterial Enzyme that Contributes to Blepharitis and Meibomian Gland Dysfunction
May 06, 2015 0 NovaBay Pharmaceuticals’ Avenova Brings Significant Improvement to Patients with Blepharitis, New Study Finds
Apr 10, 2015 0 NovaBay Pharmaceuticals to Offer Educational Workshop on Eye Lid Management at the ASCRS Annual Symposium in San Diego
Mar 26, 2015 0 NovaBay Pharmaceuticals Reports 2014 Fourth Quarter and Full Year Financial Results and Provides Business Update
Mar 17, 2015 0 The National Necrotizing Fasciitis Foundation Names NovaBay’s NeutroPhase as its Official “Flesh Eating Disease” Wound Cleanser
Jan 21, 2015 0 NovaBay Management and Key Industry Opinion Leaders to Hold Investment Community Conference Call Today, January 21st, 2015, at 12:00 p.m. ET
Dec 23, 2014 0 Christmas Gift to People Worldwide Suffering From “Flesh Eating” Disease: NovaBay Pharmaceuticals and the National Necrotizing Fasciitis Foundation Will Offer New Life- and Limb-Saving Treatment At No Charge to Patients Worldwide
Dec 16, 2014 0 China Pioneer Pharma Joins Hand with NovaBay Pharmaceuticals and the NNFF To Offer Free New Life-Saving Treatment for “Flesh-Eating” Disease
Nov 12, 2014 0 NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update
Oct 27, 2014 0 NovaBay Pharmaceuticals Receives 2nd Major NeutroPhase Order for 150,000 Units from China Pioneer Pharma
Oct 14, 2014 0 NovaBay Pharmaceuticals to Present Successful Patient Case Histories of i-Lid Cleanser Use at the 2014 American Academy of Ophthalmology Meeting
Sep 16, 2014 0 NovaBay Pharmaceuticals will Feature i-Lid Cleanser for the First Time at Vision Expo West
Sep 09, 2014 0 NovaBay Pharmaceuticals to Present at Rodman & Renshaw 16th Annual Healthcare Conference
Sep 09, 2014 0 Center Director of Omni Eye Surgery in New York City Describes a Promising New Product for the Management of Eyelid Disease in News Publication
Sep 03, 2014 0 China’s Food and Drug Administration has Cleared NovaBay’s NeutroPhase® Skin and Wound Cleanser for Sale throughout Mainland China by NovaBay’s Partner, China Pioneer Pharma
Aug 28, 2014 0 NovaBay Pharmaceuticals Adds Five Top Ophthalmologists to its Ophthalmic Advisory Board
Aug 25, 2014 0 NovaBay Pharmaceuticals Deploys Direct Sales Force to Market i-Lid Cleanser Across the U.S.
Jul 31, 2014 0 NovaBay Pharmaceuticals Reports Second Quarter 2014 Financial Results and a Clinical/Business Update
Jul 28, 2014 0 In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease
Jul 16, 2014 0 NovaBay Pharmaceuticals Announces Direct US Marketing-Sales Campaign For New i-LidTM Cleanser Product
Jun 26, 2014 0 Dr. Christine W. Sindt Will Describe Benefits of NovaBay’s i-Lid Cleanser At American Optometric Association Meeting
May 21, 2014 0 NovaBay Pharmaceuticals Announces Presentation of Positive Data From Its Clinical Trial of Auriclosene Irrigation Solution For Urinary Catheter Encrustation and Blockage
May 15, 2014 0 NovaBay Pharmaceuticals Announces Completion of Enrollment in its Global Phase 2b Clinical Trial, BAYnovation
May 01, 2014 0 NovaBay Pharmaceuticals Reports First Quarter 2014 Financial Results and a Clinical/Business Update
Apr 29, 2014 0 Chronic Wounds Cost The Nation More Than $25 Billion Per Year, Reports Ron Najafi, CEO of NovaBay Pharmaceuticals
Apr 24, 2014 0 NovaBay Pharmaceuticals’ NeutroPhase is Focus of Dr. John Crew’s Presentation at Advanced Wound Care Care Symposium
Apr 23, 2014 0 NovaBay Introduces Advanced i-Lid™ Cleanser, For Cleaning Eyelids and Skin Around The Eye
Apr 17, 2014 0 Wound Source Reports on the Role of NovaBay’s NeutroPhase® in Treatment of ‘Flesh Eating’ Bacteria
Mar 28, 2014 0 Triple Amputation From Flesh-Eating Disease in the United Kingdom Highlights Importance of NovaBay’s NeutroPhase Wound Cleanser
Mar 20, 2014 0 NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Mar 19, 2014 0 NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
Mar 07, 2014 0 NovaBay Pharmaceuticals Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides Clinical/Business Update
Mar 06, 2014 0 NovaBay CEO Comments on President Obama’s ‘SuperBug’ Budget Initiative and Reports by the CDC on Antibiotic Resistance
Feb 26, 2014 0 NovaBay Pharmaceuticals Grants Principle Business Enterprises Exclusive Marketing and Distribution Rights in the US for NeutroPhase®, an Advanced Wound and Skin Cleanser
Feb 17, 2014 0 NovaBay’s NeutroPhase Is Best In Class In Laboratory Study of 19 Top Commercial Wound Cleansers
Feb 06, 2014 0 Dr. John Crew Gives Grand Rounds Presentation on Treating Wounds with NovaBay’s NeutroPhase at Eisenhower Medical Center
Jan 28, 2014 0 Research Breakthrough For Deadly Flesh-Eating Disease Reported in the Journal Cell Highlights Importance of Neutralization of Toxins Associated with Flesh Eating Bacteria
Jan 09, 2014 0 NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek, Solta Medical Chairman and CEO and Dr. Massimo Radaelli, Noventia Pharma CEO to its Board of Directors
Dec 19, 2013 0 NovaBay Pharmaceuticals Announces Plan To Reinitiate Clinical Evaluation of Auriclosene For Impetigo in 2014
Dec 12, 2013 0 Dr. Ron Najafi, CEO of NovaBay Pharmaceuticals, Urges FDA To Formally Ban Antibiotic Use In Food Production
Dec 11, 2013 0 NovaBay Pharmaceuticals Gain ISO 13485 Certification For The Design and Manufacturing of NeutroPhase®
Dec 02, 2013 0 NovaBay Pharmaceuticals and China Pioneer Pharma Announce Expansion Of Partnership Agreement
Nov 19, 2013 0 NovaBay Pharmaceuticals Announces Publication of Novel Surgical Procedure for Life Threatening Wounds and Flesh Eating Bacteria
Nov 14, 2013 0 NovaBay Pharmaceuticals Reports Third Quarter 2013 Financial Results and a Clinical /Business Update
Oct 07, 2013 0 NovaBay Calls for New Approaches to Antibiotic Drug Development to Slow the Rise of Resistance, Save Lives and Protect the Environment
Sep 26, 2013 0 NovaBay Pharmaceuticals Releases Video of Recent Analyst and Investor Event in New York
Sep 16, 2013 0 NovaBay Pharmaceuticals Announces Positive Results from Phase 2 Clinical Study of Auriclosene to Reduce Urinary Catheter Blockage and Encrustation
Aug 01, 2013 0 NovaBay Pharmaceuticals Reports Second Quarter 2013 Financial Results and a Clinical/Business Update
May 28, 2013 0 NovaBay Pharmaceuticals and Virbac Enter Into a Collaboration and License Agreement for Animal Health
May 02, 2013 0 NovaBay Pharmaceuticals Reports First Quarter Financial Results and Clinical and Business Update
Mar 14, 2013 0 NovaBay Pharmaceuticals Reports Fourth Quarter Financial Results and 2013 Clinical and Business Update
Feb 20, 2013 0 NovaBay Receives Unique Globally Recognized International Nonproprietary Name Auriclosene for NVC-422
Dec 06, 2012 0 NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Dec 05, 2012 0 NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
Nov 26, 2012 0 NovaBay Pharmaceuticals to Present at Lazard Capital Markets 9th Annual Healthcare Conference
Sep 24, 2012 0 Galderma and NovaBay Enroll First Patients in Phase 2b Clinical Study of NVC-422 for Impetigo
Sep 14, 2012 0 NovaBay Pharmaceuticals (NBY) Announces Expansion of Strategic Marketing Agreement for NeutroPhase in Southeast Asia
Sep 13, 2012 0 NovaBays NeutroPhase Used in New Therapeutic Technique for Management of Necrotizing Fasciitis
Sep 12, 2012 0 NovaBay Pharmaceuticals Co-authors Novel Study Demonstrating Chemical Impact of N-chlorotaurine and NVC-422 on Bacterial Toxins
Sep 04, 2012 0 NovaBay Pharmaceuticals to Present at Rodman & Renshaw 14th Annual Healthcare Conference
Aug 27, 2012 0 NovaBay Pharmaceuticals Receives Additional FDA 510(k) Clearance for NeutroPhase Wound Cleanser
May 31, 2012 0 NovaBay Pharmaceuticals Strengthens Global Aganocide Patent Estate with Seven New Patents
May 17, 2012 0 NovaBay Enrolls First Patients in Global BAYnovation Phase 2b Study for Adenoviral Conjunctivitis
Apr 19, 2012 0 NovaBay’s NeutroPhase(R) Supports Healing of Chronic Wounds New Patient Case Studies Highlighted at the 2012 Spring Symposium on Advanced Wound Care
Apr 16, 2012 0 NovaBay to Present New Case Studies on NeutroPhase(R) at the 2012 Spring Symposium on Advanced Wound Care
Mar 20, 2012 0 NovaBay Pharmaceuticals Signs Option Agreement with Virbac Animal Health for Aganocide Compounds
Feb 07, 2012 0 NovaBay Pharmaceuticals to Hold Conference Call to Provide Year-end Business Update and 2012 Outlook
Jan 09, 2012 0 NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China
Nov 30, 2011 0 NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program
Oct 04, 2011 0 NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. As Head of Ophthalmic Drug Development
Sep 28, 2011 0 NovaBay Pharmaceuticals Names Russell A. Hoon As Vice President of its Advanced Wound Care Business Unit
Aug 24, 2011 0 NovaBay Pharmaceuticals to Present at The 2011 Southern California Investor Conference
Jul 05, 2011 0 NovaBay Pharmaceuticals Announces the Closing of its $5.2 Million Registered Direct Offering of Common Stock and Warrants
Jun 29, 2011 0 NovaBay Pharmaceuticals, Inc. Announces Pricing of a $5.2 Million Registered Direct Offering of Common Stock and Warrants
May 23, 2011 0 NovaBay Pharmaceuticals to Present at the 7th Annual Spring Growth Stock Conference Hosted by Security Research Associates, Inc. on May 24
May 18, 2011 0 Archive of Conference call Re: Results from Phase 2 Clinical Study for the Treatment of Adenoviral Conjunctivitis
May 18, 2011 0 NovaBay Pharmaceuticals Reports Results from Phase 2 Clinical Trial of NVC-422 for Adenoviral Conjunctivitis
May 06, 2011 0 NovaBay Pharmaceuticals Spotlights Three New Aganocide Compounds with Confirmed Activity against Ophthalmic Pathogens
Apr 19, 2011 0 NovaBay Pharmaceuticals Spotlights Positive Results From NeutroPhase Study of 26 Patients With Chronic Non-Healing Wounds
Apr 14, 2011 0 NovaBay Pharmaceuticals Awarded 1st Place for Outstanding Scientific Presentation at The Simon Foundation for Continence Conference
Apr 12, 2011 0 NovaBay Pharmaceuticals Spotlights Positive Results for Its Novel Anti-Infective at 2011 Simon Foundation for Continence Conference
Mar 28, 2011 0 NovaBay Pharmaceuticals Releases CEO Webcast on Business and Clinical Developments from Its Four Business Units
Mar 10, 2011 0 NovaBay Pharmaceuticals Provides Fourth Quarter and Full Year 2010 Financial Results and Business Unit Updates
Mar 09, 2011 0 NovaBay Pharmaceuticals to Present at the Roth Capital 23rd Annual Growth Stock Conference on March 16
Mar 02, 2011 0 NovaBay Pharmaceuticals Initiates Phase 2 Clinical Trial for the Treatment of Urinary Catheter Blockage and Encrustation
Feb 18, 2011 0 NovaBay Pharmaceuticals Ranked No. 7 in Biotech Industry in Fast Company’s Annual List of World’s Most Innovative Companies
Jan 06, 2011 0 NovaBay Pharmaceuticals Reports Activity of Aganocide NVC-422 Against Deadly “Superbug” producing NDM-1 (New Delhi Metallo-beta-lactamase-1)
Nov 29, 2010 0 NovaBay Pharmaceuticals Holds Successful FDA Meeting on Clinical Development of Aganocide® Compound NVC-422 for Impetigo
Nov 08, 2010 0 NovaBay Pharmaceuticals Awarded Cash Grant Under the U.S. Government Qualifying Therapeutic Discovery Program
Oct 25, 2010 0 NovaBay Pharmaceutical’s NVC-422 Demonstrates up to 95% Efficacy in 129 Patient Impetigo Phase 2 Clinical Trial, Including 100% Efficacy in MRSA Infected Patients
Oct 18, 2010 0 NovaBay Pharmaceuticals Reports on Status of Phase 2 Proof of Concept Clinical Trial of NovaBay’s NVC-422 for Viral Conjunctivitis
Oct 15, 2010 0 NovaBay Pharmaceuticals to Present Human Clinical Data on Lead Anti-infective Compound at the 48th Annual IDSA Meeting
Oct 11, 2010 0 NovaBay Pharmaceuticals Appoints Gail Maderis, BayBio President and CEO and Former Genzyme Senior Executive, to Its Board of Directors
Sep 16, 2010 0 NovaBay Pharmaceuticals Spotlights Positive Results for New Class of Anti-infectives at 50th Annual ICAAC Meeting
Jul 21, 2010 0 NovaBay Pharmaceuticals’ Non-antibiotic Anti-infective Successful in Phase 2 Skin Infection Trial
Jul 15, 2010 0 NovaBay Pharmaceuticals Receives Notice of Allowance on Anti-infective NVC-612 and Related Compounds
May 06, 2010 0 Positive Data on New Class of Anti-infectives Announced by NovaBay Pharmaceuticals at ARVO 2010
Apr 30, 2010 0 NovaBay Pharmaceuticals Announces New Data on First-in-Class Anti-infective Compounds at ARVO Annual Meeting
Mar 29, 2010 0 NovaBay Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
Nov 13, 2009 0 NovaBay Pharmaceuticals Reports Third Quarter 2009 Financial Results, Provides Pipeline Update
Oct 30, 2009 0 NovaBay’s Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
Oct 28, 2009 0 NovaBay to Hold Conference Call to Review Aganocide Data Presented at the Infectious Diseases Society of America Meeting
Oct 22, 2009 0 NovaBay Pharmaceuticals to Present at 8th Annual Bio Investor Forum 2009 in San Francisco
Oct 19, 2009 0 NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
Sep 24, 2009 0 NovaBay Pharmaceuticals to Present at Maxim Group Growth Conference Presentation to be Webcast on September 29, 2009
Sep 22, 2009 0 NovaBay Pharmaceuticals Is Recognized As A New California 100 Business Innovator By Golden Capital Network & Hamilton Lane
Sep 14, 2009 0 NovaBay Presents Data Confirming Its Aganocide Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
Sep 10, 2009 0 NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
Sep 03, 2009 0 NovaBay Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference September 10, 2009 in New York City
Aug 26, 2009 0 NovaBay Pharmaceuticals Announces the Closing of its $2.45 Million Registered Direct Offering of Common Stock and Warrants
Aug 24, 2009 0 NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
Aug 21, 2009 0 NovaBay Pharmaceuticals Announces Pricing of Registered Direct Offering of Common Stock and Warrants
Aug 21, 2009 0 NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
Aug 03, 2009 0 NovaBay Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
Apr 22, 2009 0 NovaBay Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide Compounds
Apr 07, 2009 0 NovaBay Pharmaceuticals Appoints Professor John A. Soderquist, Ph.D. to its Scientific Advisory Board
Mar 25, 2009 0 NovaBay Pharmaceuticals and Galderma Enter into Global Agreement to Develop and Commercialize NovaBay’s Novel Aganocide Drugs for Major Dermatological Conditions
Mar 23, 2009 0 NovaBay Pharmaceuticals Scientific Advisor Receives American Chemical Society’s Highest Award
Mar 07, 2009 0 NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
Mar 04, 2009 0 NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67 Annual Meeting
Feb 04, 2009 0 NovaBay Pharmaceuticals CEO Dr. Ron Najafi To Present at the 11th Annual BIO CEO & Investor Conference
Jan 20, 2009 0 NovaBay Pharmaceuticals Appoints Harry F. Hixson, Jr., PhD, Former Amgen President/Chief Operating Officer To Its Board of Directors
Jan 09, 2009 0 NovaBay Pharmaceuticals Issued Key Composition of Matter Patent for Aganocide Compounds
Dec 31, 2008 0 NovaBay Pharmaceuticals Plans to Consolidate its Stock Listing on the American Stock Exchange (AMEX)
Nov 18, 2008 0 Patient Enrollment Begins in Exploratory Phase II Trial of Novabay’s Lead Aganocide Compound, NVC-422, in Catherer-Associated Urinary Tract Infections
Nov 07, 2008 0 Novabay Pharmaceuticals To Present at the 10th Annual Rodman & Renshaw Healthcare Conference
Oct 07, 2008 0 NovaBay Pharmaceuticals To Present Data On Lead Anti-Infective Compound at First-Ever ICAAC/IDSA Joint Meeting
Jul 31, 2008 0 NovaBay Pharmaceuticals CEO, Dr. Ron Najafi, Joins Distinguished Leaders Selected For This Year’s PharmaVOICE 100 Most Influential Leaders
Jul 29, 2008 0 NovaBay Begins Media Education Initiative to Promote New Approaches to Treating “Super Bugs”
May 19, 2008 0 NovaBay Announces Positive Results From Phase IIa Study of AgaNase For Nasal Decolonization of Staph including MRSA
May 12, 2008 0 NovaBay’s Lead Aganocide Compound, NVC-422, Well Tolerated in the Bladder in Phase I Trial
Mar 18, 2008 0 NovaBay Pharmaceuticals Publishes on the Design of New Class of Antimicrobial Compounds It Named Aganocides
Mar 11, 2008 0 NovaBay Pharmaceuticals Reports Fourth Quarter and Year End 2007 Results, Provides Corporate Highlights
Mar 07, 2008 0 NovaBay Pharmaceuticals Commences Phase I Human Clinical Trial for the Prevention of Catheter Associated Urinary Tract Infections
Feb 26, 2008 0 NovaBay Pharmaceuticals Presentation at the 20th Annual Roth Capital OC Growth Stock Conference Featured on MSN Money
Jan 22, 2008 0 NovaBay Pharmaceutical’s Investigational New Drug Application (IND) for the Prevention of Catheter Associated Urinary Tract Infections Cleared by FDA
Dec 04, 2007 0 NovaBay Pharmaceuticals to Present at the New York Society of Security Analysts Biotech/Specialty Pharma Conference
Nov 26, 2007 0 Novabay Pharmaceuticals Announces Positive Phase 1 Study Results With Lead Aganocide Compound
